MX2022006807A - Análogos de rapamicina y usos de estos. - Google Patents

Análogos de rapamicina y usos de estos.

Info

Publication number
MX2022006807A
MX2022006807A MX2022006807A MX2022006807A MX2022006807A MX 2022006807 A MX2022006807 A MX 2022006807A MX 2022006807 A MX2022006807 A MX 2022006807A MX 2022006807 A MX2022006807 A MX 2022006807A MX 2022006807 A MX2022006807 A MX 2022006807A
Authority
MX
Mexico
Prior art keywords
present
compositions
methods
compounds
rapamycin analogs
Prior art date
Application number
MX2022006807A
Other languages
English (en)
Inventor
Eddine Saiah
David John O'neill
Seong Woo Anthony Kang
Original Assignee
Anakuria Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anakuria Therapeutics Inc filed Critical Anakuria Therapeutics Inc
Publication of MX2022006807A publication Critical patent/MX2022006807A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invención proporciona compuestos, composiciones de estos y métodos para usarlos. La presente invención se relaciona con compuestos y métodos útiles para modular la actividad de mTORC1. La invención también proporciona composiciones farmacéuticamente aceptables que comprenden compuestos proporcionados de la presente invención y métodos para usar tales composiciones en el tratamiento de diversos trastornos.
MX2022006807A 2019-12-05 2020-12-04 Análogos de rapamicina y usos de estos. MX2022006807A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962944166P 2019-12-05 2019-12-05
PCT/US2020/063351 WO2021113665A1 (en) 2019-12-05 2020-12-04 Rapamycin analogs and uses thereof

Publications (1)

Publication Number Publication Date
MX2022006807A true MX2022006807A (es) 2022-09-12

Family

ID=76222025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006807A MX2022006807A (es) 2019-12-05 2020-12-04 Análogos de rapamicina y usos de estos.

Country Status (12)

Country Link
US (1) US11819476B2 (es)
EP (1) EP4069223A4 (es)
JP (1) JP2023506410A (es)
KR (1) KR20220128345A (es)
CN (1) CN115209897A (es)
AU (1) AU2020397938A1 (es)
BR (1) BR112022010754A2 (es)
CA (1) CA3163680A1 (es)
IL (1) IL293549A (es)
MX (1) MX2022006807A (es)
TW (1) TW202134234A (es)
WO (1) WO2021113665A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021008777A (es) 2019-01-22 2022-01-06 Aeovian Pharmaceuticals Inc Moduladores de mtorc y usos de los mismos.
WO2021195599A1 (en) 2020-03-27 2021-09-30 Aeovian Pharmaceuticals, Inc. Mtorc1 modulators and uses thereof
CN116322677A (zh) * 2020-07-21 2023-06-23 艾奥维安制药公司 Mtorc1调节剂及其用途
CA3209086A1 (en) * 2021-01-22 2022-07-28 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
CN114539203A (zh) * 2022-03-10 2022-05-27 李科 一种低成本碳酸亚乙烯酯的合成方法
WO2023196676A1 (en) * 2022-04-09 2023-10-12 The Brigham And Women's Hospital, Inc. Treating tuberous sclerosis complex-associated diseases
CN115097046B (zh) * 2022-07-07 2023-09-26 国药集团川抗制药有限公司 一种分离雷帕霉素及其杂质的方法

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
WO1994025072A1 (en) 1993-04-23 1994-11-10 American Home Products Corporation Rapamycin conjugates and antibodies
WO1995014023A1 (en) 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
EP0734389B1 (en) 1993-12-17 2000-03-29 Novartis AG Rapamycin derivatives useful as immunosuppressants
US5362735A (en) 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
US5639600A (en) 1994-08-05 1997-06-17 The Regents Of The University Of California Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
JP3934705B2 (ja) * 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
CA2219080A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamycin-based regulation of biological events
ES2187660T3 (es) 1995-06-09 2003-06-16 Novartis Ag Derivados de rapamicina.
AU735648B2 (en) * 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
JP2002514165A (ja) 1996-07-12 2002-05-14 アリアド・ファーマシューティカルズ・インコーポレイテッド 病原性真菌感染の治療または予防材料および方法
CA2266039A1 (en) 1996-09-09 1998-03-12 Thomas Joseph Caggiano Alkylated rapamycin derivatives
US5922730A (en) 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
US6342507B1 (en) 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
AU755784B2 (en) * 1998-01-15 2002-12-19 Ariad Pharmaceuticals, Inc. Regulation of biological events using multimeric chimeric proteins
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
EP1212331B1 (en) 1999-08-24 2004-04-21 Ariad Gene Therapeutics, Inc. 28-epirapalogs
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
PL218519B1 (pl) 1999-12-10 2014-12-31 Pfizer Prod Inc Związki pirolo [2,3-d] pirymidynowe, środek farmaceutyczny zawierający te związki oraz ich zastosowanie
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1389617B1 (en) 2001-04-27 2007-01-03 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2319894T3 (es) 2002-08-14 2009-05-14 Silence Therapeutics Aktiengesellschaft Uso de la proteina quinasa-n-beta.
SG160211A1 (en) 2003-04-03 2010-04-29 Semafore Pharmaceuticals Inc Pi-3 kinase inhibitor prodrugs
SI1644363T1 (sl) 2003-05-30 2012-07-31 Gemin X Pharmaceuticals Canada Inc Triheterociklične spojine sestavki in postopki za zdravljenje raka
CA2531069A1 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
MXPA06000117A (es) * 2003-07-08 2006-04-27 Novartis Ag Uso de rapamicina y derivados de rapamicina para el tratamiento de perdida osea.
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
CN102229609A (zh) 2004-05-13 2011-11-02 艾科斯有限公司 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
US20060189551A1 (en) * 2004-10-04 2006-08-24 Duke University Combination therapies for fungal pathogens
RU2416616C2 (ru) 2005-01-19 2011-04-20 Райджел Фармасьютикалз, Инк. Пролекарства соединений 2,4-пиримидиндиамина и их применения
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
US20060257337A1 (en) 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
NZ583758A (en) 2005-05-12 2011-02-25 Abbott Lab Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
RS52953B (en) 2005-10-07 2014-02-28 Exelixis Inc. PYRIDOPINIDINONSKI INHIBITORI PI3 KALFA
EA024305B1 (ru) 2005-10-07 2016-09-30 Экселиксис, Инк. Ингибиторы фосфатидилинозит-3-киназы и их применение
RU2597364C2 (ru) 2005-11-01 2016-09-10 Таргеджен, Инк. Би-арил-мета-пиримидиновые ингибиторы киназ
AU2006316605B2 (en) 2005-11-17 2012-04-26 Osi Pharmaceuticals, Inc. Fused bicyclic mTOR inhibitors
WO2007070514A1 (en) 2005-12-13 2007-06-21 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US20070203168A1 (en) 2006-02-28 2007-08-30 Zhao Jonathon Z Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same
TW200815429A (en) 2006-04-11 2008-04-01 Smithkline Beecham Corp Thiazolidinedione derivatives as PI3 kinase inhibitors
CL2007001165A1 (es) 2006-04-26 2008-01-25 Hoffmann La Roche 2-(1h-indazol-4-il)-6-(4-metanosulfonil-piperazin-1-ilmetil)-4-morfolin-4-il-tieno[3,2-d]pirimidina; procedimiento de preparacion; composicion farmaceutica; proceso de preparacion de dicha composicion; kit farmaceutico; y uso para tratar enfermedades tales como cancer, desordenes inmunes y enfermedades cardiovasculares.
US20080026591A1 (en) 2006-07-28 2008-01-31 Caracal, Inc. Sintered metal components for crystal growth reactors
RS51927B (en) 2006-09-15 2012-02-29 Pfizer Products Inc. PIRIDO (2,3-D) PIRIMIDINONE COMPOUNDS AND THEIR USE AS INHIBITORS P13
SI2530083T1 (sl) 2006-09-22 2016-09-30 Pharmacyclics Llc Inhibitorji Bruton tirozin kinaze
CA2671782C (en) 2006-12-07 2017-01-10 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
WO2008110491A2 (en) 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
RS54533B1 (en) 2007-03-12 2016-06-30 Ym Biosciences Australia Pty Ltd PHENYL AMINOPYRIMIDINE COMPOUNDS AND THEIR APPLICATIONS
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
TWI444382B (zh) 2008-03-11 2014-07-11 Incyte Corp 作為ｊａｋ抑制劑之氮雜環丁烷及環丁烷衍生物
US20090253733A1 (en) 2008-04-02 2009-10-08 Biointeractions, Ltd. Rapamycin carbonate esters
ME01111B (me) 2008-05-23 2013-03-20 Wyeth Llc Triazinska jedinjenja kao inhibitori p13 kinaze i mtor
AU2009261688B2 (en) 2008-06-20 2012-07-05 Astrazeneca Ab Compositions with and process for methylmorpholin-substituted pyrido [2,3-D] pyrimidines
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
TW201038567A (en) 2009-03-27 2010-11-01 Pathway Therapeutics Ltd Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
RU2506264C2 (ru) 2009-04-03 2014-02-10 Вэрастэм, Инк. Пиримидин-замещенные пуриновые соединения в качестве ингибиторов киназы (или киназ)
US20100305093A1 (en) 2009-04-09 2010-12-02 Exelixis, Inc. Inhibitors of mTOR and Methods of Making and Using
ES2689177T3 (es) 2010-04-13 2018-11-08 Novartis Ag Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer
CA2805608A1 (en) 2010-07-16 2012-01-19 Piramal Enterprises Limited Substituted imidazoquinoline derivatives as kinase inhibitors
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
US8808256B2 (en) 2012-01-16 2014-08-19 Johnson & Johnson Vision Care, Inc. Eye drug delivery system
US9072678B2 (en) 2013-03-14 2015-07-07 Pathak Holdings Llc Methods for local drug delivery by microinjection
US9663508B2 (en) 2013-10-01 2017-05-30 Amgen Inc. Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
PE20161372A1 (es) 2014-02-03 2017-01-08 Vitae Pharmaceuticals Inc Inhibidores de dihidropirrolopiridina de ror-gamma
MX2017001981A (es) 2014-09-11 2017-12-12 Univ California Inhibidores de diana de rapamicina en celulas de mamifero de complejo 1 (mtorc1).
US20160279108A1 (en) 2015-02-24 2016-09-29 University Of Kansas Targeted mtor inhibitors
US10683308B2 (en) * 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CA3061907A1 (en) 2017-05-02 2018-11-08 Revolution Medicines, Inc. Rapamycin analogs as mtor inhibitors
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
US10980784B2 (en) * 2018-06-15 2021-04-20 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
WO2020076738A2 (en) * 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
AU2019409366B2 (en) 2018-12-18 2022-10-27 Novartis Ag Rapamycin derivatives
MX2021008777A (es) * 2019-01-22 2022-01-06 Aeovian Pharmaceuticals Inc Moduladores de mtorc y usos de los mismos.
US20220202787A1 (en) 2019-03-26 2022-06-30 Novartis Ag Isothiazolidine 1,1-dioxide and 1,4-butan sultone containing rapamycin derivatives and uses thereof
WO2021195599A1 (en) 2020-03-27 2021-09-30 Aeovian Pharmaceuticals, Inc. Mtorc1 modulators and uses thereof
CN116322677A (zh) 2020-07-21 2023-06-23 艾奥维安制药公司 Mtorc1调节剂及其用途

Also Published As

Publication number Publication date
CN115209897A (zh) 2022-10-18
EP4069223A1 (en) 2022-10-12
WO2021113665A1 (en) 2021-06-10
US20210186935A1 (en) 2021-06-24
KR20220128345A (ko) 2022-09-20
CA3163680A1 (en) 2021-06-10
AU2020397938A1 (en) 2022-06-23
EP4069223A4 (en) 2023-12-20
JP2023506410A (ja) 2023-02-16
TW202134234A (zh) 2021-09-16
IL293549A (en) 2022-08-01
US11819476B2 (en) 2023-11-21
BR112022010754A2 (pt) 2022-08-23

Similar Documents

Publication Publication Date Title
MX2022006807A (es) Análogos de rapamicina y usos de estos.
AU2018236800B2 (en) DNA-PK inhibitors
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
CR20220316A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
MX2021010304A (es) Pirimidina-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos.
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
CR20220234A (es) Degradadores de moléculas pequeñas de helios y procedimientos de uso
PH12020552092A1 (en) Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
WO2014100071A3 (en) Substituted pyrrolopyrimidines as hdm2 inhibitors
IL207976A0 (en) Novel 02x7r antagonists and their use
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
WO2019078968A3 (en) Cyclic compounds as immunomodulating agents
GEP20247585B (en) Furoindazole derivatives
MX2021007247A (es) Derivados de rapamicina.
MX2022002597A (es) Métodos de tratamiento de la epilepsia usando los métodos.
MX2021013602A (es) Inhibidores de jak.
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis